Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revvity, Inc. Common Stock (NY: RVTY )

110.32 -1.20 (-1.08%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,479,921
Open 110.71
Bid (Size) 108.11 (1)
Ask (Size) 125.00 (5)
Prev. Close 111.52
Today's Range 109.96 - 112.44
52wk Range 97.31 - 129.50
Shares Outstanding N/A
Dividend Yield 0.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What Does the Market Think About Revvity?
Via Benzinga
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
From Revvity
Via Business Wire

Performance

YTD
-1.50%
-1.50%
1 Month
-3.94%
-3.94%
3 Month
-5.42%
-5.42%
6 Month
-8.83%
-8.83%
1 Year
+1.39%
+1.39%

More News

Read More
Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks
Via StockStory
Topics Economy
Exposures Supply Chain
3 Reasons to Sell RVTY and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
Exposures US Equities
(RVTY) - Analyzing Revvity's Short Interest
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Revvity
Via Benzinga
These Analysts Revise Their Forecasts On Revvity Following Q3 Results
Via Benzinga
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
From Revvity
Via Business Wire
Revvity to Present at Upcoming Investor Conferences
From Revvity
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
Revvity (NYSE:RVTY) Reports Q4 In Line With Expectations
Via StockStory
Friday's pre-market session: top gainers and losers in the S&P500 index
Via Chartmill
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
From Revvity
Via Business Wire
Earnings Scheduled For January 31, 2025
Via Benzinga
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
From Revvity
Via Business Wire
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
From Revvity
Via Business Wire
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
From Revvity
Via Business Wire
Revvity to Present at J.P. Morgan Healthcare Conference
From Revvity
Via Business Wire
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
Via Benzinga
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
From Revvity
Via Business Wire
Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
From Scale Biosciences
Via Business Wire
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference
From Revvity
Via Business Wire
Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation
From Revvity
Via Business Wire
Revvity Announces Financial Results for the Third Quarter of 2024
From Revvity
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.